(Photo Credit: NextCure) Quality Culture Runs Deep at NextCure For many companies, Quality is only addressed out in the open after something goes wrong. By then, it’s often too late [….]
Quality Culture Runs Deep at NextCure
NextCure Announces Development of a Highly Specific Immunohistochemical Diagnostic for Siglec-15-positive Tumors as reported in Laboratory Investigation
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the publication of a paper titled “Development of an Immunohistochemical Assay for Siglec-15” in Laboratory Investigation. The publication outlines data from a study, conducted in collaboration with researchers in the Department of Pathology at Yale School of Medicine, utilizing a newly developed antibody to Siglec-15 (S15) and an immunhistochemical (IHC) assay to investigate S15 expression in solid tumors.
In Conversation: Stacy Rollinger, VP of Human Resources at NextCure
NextCure recently brought on a new Vice President of Human Resources, Stacy Rollinger, SPHR, to lead the human resources function and drive talent acquisition activities. We caught up with Rollinger to discuss her career journey, NXTC’s workplace culture, the company’s talent acquisition approach, and its future hiring goals.
WATCH NOW: Michael Richman on NextCure’s Cancer Treatment Innovations and the Rise of Biotech in Maryland
American Gene Technologies CEO Jeff Galvin sits down with Michael Richman, President & CEO of NextCure, Inc. NextCure is a clinical-stage biopharmaceutical company developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. With four clinical readouts and another IND application for a fourth program expected this year, NextCure is proving to be an emerging leader in immuno-oncology.
5 Questions with Jason Bosiacki, Associate Director, Manufacturing Operations at NextCure
Jason received his bachelor’s degree in biology with a minor in chemistry from Frostburg State University. He has been in the biotech industry for 12 years, having spent most of that time in R&D, primarily immunology and in the manufacturing of biologics, making monoclonal antibodies and fusions proteins.
NextCure Featured on Business Spotlight Video Series
NextCure, an emerging global leader in developing novel immunomedicines to treat cancer and other immune-related diseases, was recently featured on Prince George’s County Economic Development Corporation’s (PGCEDC) Business Spotlight video series.
Maryland Life Science Companies Share Hopes for Annual BIO Convention
Over a period of four days, life sciences companies from across the globe will descend on San Diego for the annual Biotechnology Innovation Organization (BIO) meeting. Multiple companies from Maryland, as well as the Department of Commerce, will be among them, showcasing the strength of the BioHealth Capital Region.
NextCure Provides Business Update and Reports First Quarter 2022 Financial Results
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today reported first quarter 2022 financial results and provided a business update.
In Conversation: Shannon Biermann, Senior Quality Control Manager – Microbiology at NextCure
BioBuzz recently spoke with Shannon Biermann, who is a Senior Quality Control Manager of Microbiology at Beltsville, MD-based NextCure, to learn more about how she’s navigated her career in Microbiology QC thus far and how NextCure’s unique company culture helped her to take ownership and propel her career to the next level.
How Science and the Arts are Intermixing in the BioHealth Capital Region
It’s an age-old thinking that the arts and sciences mix as well as oil and water, with artists being stereotyped as whimsical, quirky, and creative, and scientists as analytical, awkward, and calculating. Folks who use the acronym “STEAM” instead of “STEM”, which accounts for the addition of “Art”, are often met with criticism from folks who think that the arts are not technically rigorous enough to warrant inclusion.